Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin™ in Dogs

SentiKin™, KindredBio’s third lead product candidate, is being developed for the treatment of post-operative pain in dogs.

SAN FRANCISCO, California. (March 28, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.

SentiKin is a centrally acting non-opioid, non-steroidal anti-inflammatory and non-steroidal analgesic drug. The proposed mechanism of action of SentiKin’s active ingredient is selective potassium channel opening activity with NMDA receptor antagonist properties, with resultant anti-nociceptive, anti-seizure, muscle relaxant, and neuroprotective activities. Richard Chin, Chief Executive Officer of KindredBio, stated, “We are excited to begin our third pivotal study, as we continue to pursue our mission of developing therapies for our animal family members.”

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company’s lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.

Forward-Looking Statements

Forward-looking statements in this news release involve inherent risks and uncertainties, and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to, uncertainties inherent in animal drug development and the regulatory review process and other risks described in the Company’s Annual Report on Form 10-K filed on March 14, 2014 with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this news release.

Denise Bevers
(650) 701-7909